Human Umbilical Cord Mesenchymal Stem Cells for Adjuvant Treatment of a Critically Ill COVID-19 Patient: A Case Report

BACKGROUND: COVID-19 (coronavirus disease 2019) has become a global public health emergency since patients were first detected in Wuhan, China, in December 2019. Currently, there are no satisfying antiviral medications and vaccines available. CASE PRESENTATION: We reported the treatment process and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yue, Zhu, Rongjia, Liu, Kun, Li, Xin, Chen, Dezhong, Bai, Dunyao, Luo, Jieli, Liu, Yixun, Zhang, Yan, Li, Li, Hu, Junfang, Xu, Dayong, Liu, Yan, Zhao, Robert Chunhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532065/
https://www.ncbi.nlm.nih.gov/pubmed/33061476
http://dx.doi.org/10.2147/IDR.S272645
Descripción
Sumario:BACKGROUND: COVID-19 (coronavirus disease 2019) has become a global public health emergency since patients were first detected in Wuhan, China, in December 2019. Currently, there are no satisfying antiviral medications and vaccines available. CASE PRESENTATION: We reported the treatment process and clinical outcome of a 48-year-old man critically ill COVID-19 patient who received transfusion of allogenic human umbilical cord mesenchymal stem cells (UC-MSCs). CONCLUSIONS: We proposed that UC-MSC transfusion might be a new option for critically ill COVID-19. Although only one case we were shown, more similar clinical cases are inquired for further evidence providing the potential effectiveness of UC-MSC treatment.

Ejemplares similares